AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics.
BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division.
BioPharmics has developed a series of algorithms and software for 3D ligand-based and structure-based computational drug design, including software for 2D to 3D ligand conversion and conformer generation, molecular docking, molecular similarity, and binding affinity prediction.
The acquisition follows a long-standing collaboration between the two companies, including partnering on the development of the Surflex eSim3D StarDrop module.
In their new roles, Ajay and Ann will continue the research and application of novel methods to extend the application of 3D modelling to traditional small molecules, as well as to beyond Rule-of-Five compounds that are becoming increasingly prevalent in drug discovery.